Protection From SARS-CoV-2 Infection With an Oral Nosode (BiosimCovex): A Randomized, Double-Blind, Placebo-Controlled, Phase III Study
Open Access
- 1 September 2025
- journal article
- Published by SAGE Publications in Global Advances in Integrative Medicine and Health
- Vol. 14
Abstract
Background and Objectives: This study investigated a potentized, oral homeopathic SARS-CoV-2 nosode (BiosimCovex) for safety, efficacy, and immunogenicity against COVID-19 infection. Methods: A phase III, multicentre, randomised, double-blind, placebo-controlled trial was conducted at 13 sites in India. 2671 unvaccinated, RT-PCR and SARS-CoV-2 antibody-negative participants were randomized 2:1 to receive 6 doses over 3 days of BiosimCovex (1781) or placebo (890). SARS-CoV-2 prevention efficacy was assessed through RT-PCR. Efficacy was defined as 100 x (1-IRR), where IRR is the ratio of positive RT-PCR test rates in the BiosimCovex compared to the placebo group. A two-sided Clopper-Pearson 95% confidence interval was adjusted for surveillance time. Immunogenicity was measured by SARS-CoV-2 antibody conversion at days 15, 30, 45, and 60. Safety was assessed through symptom questionnaires and laboratory studies every 15 days. Illness burden was assessed through symptom diaries. Results: Maximum efficacy occurred at day 45 and was 50.06% overall, 71.88% in individuals aged 18-40 years; and 61.57% in females. By day 45, there were 23 positive RT-PCR cases per group (BiosimCovex 1.3%; placebo 2.6%, P = 0.007). A total of fifty-nine positive RT-PCR cases occurred, with thirty-three (1.86%) in the BiosimCovex and twenty-six (2.94%) in the placebo group, for a relative risk (RR) of 0.63 at the end of the study over 60 days. Antibody conversion increased over time, with 48.4% becoming antibody positive by day 60 in the treatment group compared to 13.4% in the placebo group ( P < 0.001). All 169 (6.33%) mild adverse events resolved without sequelae (6.52% in treatment; 5.96% in placebo). There was a significant reduction in symptom duration ( P = 0.0085) in the treatment group for those who became ill. Conclusions: A potentized oral nosode was safe and appeared to prevent SARS-CoV-2 infection and be immunogenic over 60 days. Effectiveness was highest at day 45 in females and in the 18- to 40-year-old age group.Keywords
Funding Information
- SaluGenics
- H&S Ventures and Biosimilia funded the project
This publication has 31 references indexed in Scilit:
- Preparation, standardization and in vitro safety testing of Mycobacterium nosodes (Emtact- polyvalent nosode)Homeopathy, 2016
- A homeopathic nosode, Hepatitis C 30 demonstrates anticancer effect against liver cancer cells in vitro by modulating telomerase and topoisomerase II activities as also by promoting apoptosis via intrinsic mitochondrial pathwayJournal of Integrative Medicine, 2016
- A Clinical Evaluation of a Hepatitis C Nosode in the Treatment of Hepatitis CThe Journal of Alternative and Complementary Medicine, 2016
- HIV Nosode: The Homeopathic Pathogenetic TrialComplementary Medicine Research, 2015
- Extreme homeopathic dilutions retain starting materials: A nanoparticulate perspectiveHomeopathy, 2010
- Large-scale application of highly-diluted bacteria for Leptospirosis epidemic controlHomeopathy, 2010
- Homeopathy as replacement to antibiotics in the case of Escherichia coli diarrhoea in neonatal pigletsHomeopathy, 2010
- Undisclosed Changes in Outcomes in Randomized Controlled Trials: An Observational StudyThe Annals of Family Medicine, 2009
- Characterization of the structure of ultra dilute sols with remarkable biological propertiesMaterials Letters, 2008
- Immunology and Homeopathy. 1. Historical BackgroundEvidence-Based Complementary and Alternative Medicine, 2005